Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017; 9. pii: E41.Rundle S, Bradbury A, Drew Y and Curtin NJ. Targeting the ATR-CHK1 Axis in cancer therapy. Cancers (Basel) 2017; 9....
Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin. Cancer Res. 23, 3097–3108 (2017). Article PubMed CAS Google Scholar Ogiwara, H. et al. Curcumin suppresses multiple DNA damage response pathways and has potency as a ...
Nature Reviews Cancer volume 11, pages 393–410 (2011)Cite this article 38k Accesses 2536 Citations 48 Altmetric Metrics details Key Points Hypoxia represents a compelling therapeutic target, given that it has a major role in tumour development and resistance to therapy, and that the levels of ...
The mTOR signaling pathway has critical roles in mammalian metabolism and physiology. The de-regulated activity of mTOR is involved in many pathophysiological conditions, such as aging, Alzheimer’s disease, diabetes, obesity, and cancer [2]. As a natural inhibitor of mTORC1, rapamycin is able t...
Hypoxia represents a compelling therapeutic target, given that it has a major role in tumour development and resistance to therapy, and that the levels of hypoxia are more severe in most tumours than normal tissues. One approach to targeting hypoxia seeks to develop bioreductive prodrugs that are...
These ssDNA structures trigger proapoptotic signaling through the RPA/ATRIP/ATR/Chk1/p53/Puma axis, ultimately leading to the apoptotic demise of ATM-defective cells exposed to DNA-PKcs inhibitors. Finally, we demonstrate that DNA-PKcs inhibitors are effective as single agents against ATM-defective...
Loss of p53 pathway function gives cancer cells a survival advantage to bypass the resolution of oncogenic signals and DNA damage to continue abnormal proliferation. It is not taken as a surprise that when p53 was first discovered in 1979 it was thought to be an oncogene given that its ...
Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell death (RCD), also known as programmed cell death (PCD), has been widely
Small cell lung cancer (SCLC) is a difficult to treat subtype of lung cancer. One of the hallmarks of SCLC is its almost uniform chemotherapy sensitivity. However, chemotherapy response is typically transient and patients frequently succumb to SCLC withi
Ovarian cancer remains the most lethal gynecological malignancy. Despite the approval of promising targeted therapy such as bevacizumab and PARP inhibitors, 5-year survival has not improved significantly. Thus, there is an urgent need for new therapeutic